News Search Results
Dec 02, 2025, 08:15 ET AbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers
FL.2Fixed-Duration Venetoclax (BCL-2 Inhibitor) Regimens in Previously Untreated CLLInterim data will be showcased from the randomized, Phase 3 CLL17 trial (
More news about: AbbVie Inc.
Dec 02, 2025, 08:00 ET Rutgers Cancer Institute and RWJBarnabas Health to Showcase Practice-Changing Blood Cancer Research at the 67th American Society of Hematology Annual Meeting and Exposition
real-world evidence study investigated racial and ethnic inequities in access to guideline-preferred first-line therapies for chronic lymphocytic leukemia (CLL). Using data from 4,452 patients in the Flatiron Health Research Database linked with neighborhood-level social determinants of health, researchers found
More news about: Rutgers Cancer Institute and RWJBarnabas Health
Nov 24, 2025, 12:00 ET Lilly to present data from two positive Phase 3 studies of Jaypirca (pirtobrutinib) in chronic lymphocytic leukemia at the 2025 American Society of Hematology (ASH) Annual Meeting
Results from the Phase 3 BRUIN CLL-313 study of pirtobrutinib in patients with treatment-naïve CLL/SLL will be featured as a late-breaking oral presentationBoth BRUIN CLL-314 and BRUIN CLL-313 were selected to be part of the official ASH press program
More news about: Eli Lilly and Company
Nov 21, 2025, 12:39 ET Hackensack Meridian John Theurer Cancer Center Unveils Research at the 67th American Society of Hematology Annual Meeting
from KOMET-007 (ABSTRACT 25-3910) MRD-guided therapy of sonrotoclax (BGB-11417) + obinutuzumab (O) in patients with treatment-naive CLL: Initial results from an ongoing phase 1/1b study, BGB-11417-101 (ABSTRACT 25-7489) Real world outcomes of bispecific T-cell engagers
More news about: Hackensack Meridian John Theurer Cancer Center
Nov 14, 2025, 12:30 ET AbbVie Partners with Award-Winning Filmmaker on Film About the Dynamic and Resilient Lives of Those Living with Blood Cancer
Film captures inspiring journeys of three individuals living with chronic lymphocytic leukemia (CLL) CLL is one of the most common leukemias among adults affecting more than 200,000 people in the United States1,2
More news about: AbbVie
Nov 10, 2025, 08:00 ET Cellex Symposium 2025 Brings Together International Experts to Discuss the Evolving Field of Cell and Gene Therapy
and Dr. Marcus Dühren-von Minden, SinABiomedics showcased innovations in CAR-T manufacturing and the development of the first tumor-specific CAR-T for CLL. These discussions emphasized a central message: CMC capabilities are not merely operational necessities – they are strategic
More news about: Cellex Cell Professionals
Nov 10, 2025, 08:00 ET Das Cellex-Symposium 2025 führt internationale Experten zusammen, die über die Entwicklungen im Bereich der Zell- und Gentherapie diskutieren
und Dr. Marcus Dühren-von Minden von SinABiomedics Innovationen in der CAR-T-Herstellung und die Entwicklung des ersten tumorspezifischen CAR-T für CLL vorstellten. Diese Diskussionen betonten eine zentrale Botschaft: CMC-Fähigkeiten sind nicht nur operative Notwendigkeiten, sondern
More news about: Cellex Cell Professionals
Nov 10, 2025, 08:00 ET Cellex Symposium 2025 Brings Together International Experts to Discuss the Evolving Field of Cell and Gene Therapy
and Dr. Marcus Dühren-von Minden, SinABiomedics showcased innovations in CAR-T manufacturing and the development of the first tumor-specific CAR-T for CLL. These discussions emphasized a central message: CMC capabilities are not merely operational necessities – they are strategic
More news about: Cellex Cell Professionals
Nov 10, 2025, 08:00 ET Cellex Symposium 2025: debate sobre el campo en evolución de la terapia celular y génica
Dühren-von Minden, de SinABiomedics, presentaron innovaciones en la fabricación de células CAR-T y el desarrollo de la primera célula CAR-T específica para CLL. Estos debates enfatizaron un mensaje central: las capacidades de CMC no son meras necesidades operativas, sino facilitadores
More news about: Cellex Cell Professionals
Nov 06, 2025, 16:00 ET Curis Provides Third Quarter 2025 Business Update
emavusertib + BTKi in CLL, we are working to activate clinical sites, and we expect to enroll our first patient in late Q4 or early Q1, with data expected at the ASH annual meeting in December 2026. I am very pleased with the progress we have made across multiple ongoing studies in PCNSL, CLL, and AML," said
More news about: Curis, Inc.
Nov 03, 2025, 22:23 ET 【2025 ASH】 亞盛醫藥Bcl-2抑制劑利沙托克拉兩項臨床研究入選，含1項口頭報告！
study of lisaftoclax monotherapy for treatment of patients (pts) with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who had failed Bruton's tyrosine kinase inhibitors (BTKis)
More news about: 亞盛醫藥
Nov 03, 2025, 20:22 ET 【2025 ASH】亞盛醫藥耐立克®多項研究入選，POLARIS-1研究數據首次發布
lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who had failed Bruton's tyrosine kinase inhibitors (BTKis)
More news about: 亞盛醫藥
Oct 30, 2025, 06:45 ET Lilly reports third-quarter 2025 financial results, highlights R&D pipeline momentum and raises 2025 guidance
the first and only approved non-covalent (reversible) BTK inhibitor, significantly improved progression-free survival in patients with treatment-naïve CLL/SLL (
More news about: Eli Lilly and Company
Oct 28, 2025, 17:31 ET CAR T-cell Therapy Market Forecasts Indicate Strong Growth Trajectory in the 7MM During the Forecast Period (2025-2034) | DelveInsight
Track Designation (FTD) by the U.S. FDA for the treatment of relapsed or refractory large B-cell lymphoma (LBCL) and chronic lymphocytic leukemia (CLL) following two or more prior therapies. The anticipated launch of these emerging therapies are poised to transform the CAR T-cell
More news about: DelveInsight Business Research, LLP
Oct 17, 2025, 09:00 ET Precision Oncology Approaches Drive $312B Market Transformation
$428.8 million as of August 31, 2025. "Nurix is preparing to initiate pivotal studies for bexobrutideg in relapsed/refractory CLL patients in the fourth quarter of 2025 and we have outlined our plans for potential accelerated approval with a single arm study as well as a confirmatory
More news about: USA News Group
Oct 16, 2025, 17:31 ET Indolent Lymphoma Market Experiences Significant Growth Amid Evolving Therapeutic Landscape | DelveInsight
years to advance. Key subtypes include follicular lymphoma, marginal zone lymphoma, and small lymphocytic lymphoma (SLL)/chronic lymphocytic leukemia (CLL). Many individuals may experience no symptoms for extended periods, but common signs can include painless swollen lymph nodes, fatigue, night sweats,
More news about: DelveInsight Business Research, LLP
Oct 08, 2025, 12:41 ET Olympus to Highlight Versatile ENT Portfolio of Hybrid Endoscopy and Advanced Imaging at AAO, ARS Annual Meetings
cords and detect small changes in vibration, when there are diagnostic doubts surrounding vocal cord lesions. When compared to its predecessor, the CLL-S1, the VISERA S video platform's strobe enables a brighter image with less blur during stroboscopy procedures.1 Meeting attendees can view
More news about: Olympus Corporation of the Americas
Oct 07, 2025, 06:10 ET Ryght AI Assembles Renowned Medical Leaders to Guide Next Phase of Clinical Trial AI Innovation
Professor and Head, Department of Dermatology, St George Hospital Alan Skarbnik, MD Director, Lymphoma & CLL Program, Director Immune Effector Cell Therapeutics Program, Novant Health Vivek Subbiah, MDChief, Early-Phase Drug
More news about: Ryght
Oct 06, 2025, 16:01 ET PM360 2025 Trailblazer Awards Winners Announced: Top Companies, Marketers, CEOs, Products, and Initiatives Honored at Gala, Sept. 30th
INTELLIGENCE/DATA ANALYTICS INITIATIVE GOLD WINNER:Listening Between the Lines: How Imbruvica Tapped Passive Intelligence to Humanize the CLL Journey (Inizio Evoke, Johnson & Johnson Innovative Medicine, and Pharmacyclics LLC, an AbbVie company)
More news about: PM360